San Marcos, CA, United States of America

Michael Martin

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 55(Granted Patents)

Location History:

Carlsbad, CA (US) (2015 - 2017)
Royce City, TX (US) (2021)
San Marcos, CA (US) (2014 - 2022)
Royse City, TX (US) (2023)

Company Filing History:

6 out of 108

Infinity Pharmaceuticals, Inc.

Innovative Signal Analysis, Inc.

patents

4. 1 out of 140

Sigma-aldrich Co. LLC

patents

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11770506 - Multi-source 3-dimensional detection and tracking (2023-09-26),

2. 11312718 - Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (2022-04-26),

3. 11039044 - Target detection and mapping using an image acqusition device (2021-06-15),

4. 10550122 - Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof (2020-02-04),

5. 9840505 - Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof (2017-12-12),

6. RE46621 - Processes for preparing isoquinolinones and solid forms of isoquinolinones (2017-12-04),

7. 9669032 - Enhanced treatment regimens using mTOR inhibitors (2017-06-06),

8. 9403820 - Kinase inhibitor polymorphs (2016-08-02),

9. 9290497 - Processes for preparing isoquinolinones and solid forms of isoquinolinones (2016-03-22),

10. 9174994 - Enhanced treatment regimens using mTor inhibitors (2015-11-03),

11. 8809349 - Processes for preparing isoquinolinones and solid forms of isoquinolinones (2014-08-19),

Title: Innovative Contributions of Michael Martin in Modulating Kinase Activity

Introduction

Michael Martin, an accomplished inventor based in San Marcos, California, holds an impressive portfolio of nine patents. His work predominantly focuses on pharmaceutical innovations, particularly in developing formulations and solid forms of compounds that modulate kinase activity. His contributions have significant implications for treating diseases associated with such activities.

Latest Patents

Among his latest patents are formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one. These patents detail polymorphs of chemical compounds that modulate kinase activity, including phosphoinositide 3-kinase (PI3K) activity. The documents describe various compounds, pharmaceutical compositions, and methods of treatment for diseases linked to kinase activity. Furthermore, the patents outline processes for preparing these compounds and their respective polymorphs, as well as pharmaceutical compositions that can be utilized in clinical settings.

Career Highlights

Michael has had a remarkable career, contributing his expertise to prominent companies in the pharmaceutical realm. Notably, he has worked with Infinity Pharmaceuticals, Inc. and Intellikine LLC. His innovative spirit and dedication have been pivotal in advancing pharmaceutical science and technology.

Collaborations

Collaboration is key to innovation, and Michael Martin has worked alongside esteemed colleagues such as Pingda Ren and Paul Isbester. These partnerships have enriched his research and allowed him to drive forward the development of critical therapeutic solutions.

Conclusion

Michael Martin's contributions to the field of pharmaceuticals through his numerous patents showcase his commitment to advancing science and healthcare. His work will undoubtedly continue to impact the treatment of various diseases, elevating the standards of pharmaceutical innovation in the industry.

This text is generated by artificial intelligence and may not be accurate.